Surrey Heartlands

Joint Formulary & PAD

Oxybutynin - Overactive bladder (adults)

You are here : Home > Formulary Search > Oxybutynin - Overactive bladder (adults)

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Green (see narrative)
Formulations :
  • Patches
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
Guidelines BNF SPC
R
Restrictions / Comments :
Important
Solifenacin 1mg/ml oral SUSPENSION is preferred for patients with swallowing difficulties. Oxybutynin patches are reserved for patients where an oral formulation is not suitable
 

Status 2

Non Formulary
Formulations :
  • Modified release tablets
  • Oral solution
  • Tablets
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
Guidelines BNF SPC
NFD1
Restrictions / Comments :
Important
Switch to solifenacin recommended (if appropriate).
 

Status 3

See narrative
Formulations :
  • Intravesical
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
Guidelines BNF SPC
NFD2
Restrictions / Comments :
Important

This drug has not yet been assessed for inclusion on the formulary. Contact your pharmacy team for advice on making an application to the APC.

This drug/device has not yet been assessed for formulary status [for this indication] and is not currently on the APC work-plan.

This drug/device has not yet been evaluated by the Surrey Heartlands ICS Area Prescribing Committee (APC).  As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined. 

Before prescribing this drug/device it is recommended that clinicians contact their Medicines Optimisation team to discuss possible alternatives/options.

The APC will consider recommending the prescribing of this treatment upon submission of a formal request with its associated evidence. Clinicians can contact syheartlandsicb.APC@nhs.net  if they wish to make a submission.

Documentation

Guidelines (Local)
Selection tool for OAB treatments - Nov 2024
Webpage
NICE NG123 Urinary-incontinence-and-pelvic-organ-prolapse-in-women
Webpage
NICE Clinical guideline [CG97] : Lower urinary tract symptoms in men: management
Webpage
LUTS in Men - Management of Overactive Bladder - CKS guidance
Webpage
Urinary incontinence in women - CKS guidelines
Patient resource
Leaflet-for-trial-of-stopping-OAB-drugs - anticholinergics - Mar 24

PAD Profile

ChemicalSubstance :
Oxybutynin
Indication :
Overactive bladder (adults)
Group Name :
Keywords :
OAB, urinary frequency, urge incontinence, urinary incontinence, LUTS, anticholinergics, antimuscarinics
Brand Names Include :
Cystrin, Ditropan, Lyrinel XL
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Overactive bladder (adults)
Supporting Documents :
6
Traffic Light Entries :
3

Other Indications

Below are listed other indications that Oxybutynin is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Overactive bladder (adults).

Committee Recommendations (2)

06 Mar 24 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The APC supports patients in trialling a treatment break of their overactive bladder medicines.

A "Leaflet for trial of stopping anticholinergics" can be found in the documents section below.

05 Jul 23 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

Oxybutynin immediate-release and modified-release tablets are non-formulary. A switch from oxybutinin tablets to solifenacin is recommended (where appropriate).

Patients with swallowing difficulties

Solifenacin oral SUSPENSION 1mg/ml sugar free is the preferred treatment option.

Oxybutynin patches should be reserved for patients in whom an oral route is not suitable. 

See Selection Tool for locally agreed OAB treatment options